Who's Who

Jin Young Park

Scientist

Prevention and Implementation Group


Specialty:

Epidemiology

Academic Degrees

YearDegreeMajorInstitutionTownCountry
2012PhDEpidemiologyUniversity of CambridgeCambridgeUK
2007MPhilEpidemiologyUniversity of CambridgeCambridgeUK
2006MScPublic Health, NutritionLondon School of Hygiene & Tropical MedicineLondonUK


Current Research Projects

  • GISTAR study: In collaboration with Latvia University we are conducting a study to investigate the impact of HP eradication and assessment of chronic atrophic gastritis (pepsinogens) on GC incidence and mortality (GISTAR) in several Eastern European countries. Approx. 30,000 subjects aged 40-64 are randomized to 1) screening for HP, pepsinogen, with referral of subjects with serologic evidence of atrohpic gastritis to endoscopy and treatment of HP positive subjects or 2) No intervention. A 15-year follow-up is anticipated to evaluate impact on GC mortality. Pilot work with 3,400 participants has been recently completed in Latvia and the main trial is currently underway.
    • Leja M, Park JY, Plummer M, and Herrero R. Multicentre randomized study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality (Gastric cancer prevention study by predicting atrophic gastritis; GISTAR). In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 147-153. 2014

  • HELPER study: We have initiated a randomized clinical trial in collaboratio with the National Cancer Center of Korea to evaluate the impact of HP eradication on GC incidence (HELPER) within the Korean National Screening Programme (KNSP) taking advantage of the high coverage endoscopic screening programme. Approx. 13,000 subjects aged 40-65 who undergo endoscopy as part of KNSP are invited to the study. HP positive subjects are randomized to treatment or placebo with follow up through KNSP (endoscopy every two years) for 10 years. The relatively high detection rate of early GC will facilitate the study. A series of biomarkers and additional endpoints are also envisioned.
    • Choi IJ, Park JY, and Herrero R. Effect of Helicobacter pylori eradication on gastric cancer prevention in the Republic of Korea: a randomized controlled clinical trial. In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 154-160. 2014

  • ENIGMA study: The ENIGMA study consists of a series of international prevalence surveys in high and low gastric cancer (GC) risk areas: prevalence surveys of H. pylori (HP) infection (ENIGMA I); and prevalence studies of gastric histological changes (ENIGMA II). ENIGMA I includes age-stratified random samples of subjects aged 1-69 and investigates age-specific HP prevalence and cofactors that could explain the regional differences, in addition to predicting future rates of GC and assessing antibiotic resistance in each area. In ENIGMA II, we propose to investigate the epidemiology of gastric premalignant conditions among the ENIGMA I participants aged >40 years. By collecting standardized data, we aim to investigate the epidemiology of gastric premalignant conditions and the role of bacterial, environmental and host factors.

  • EPIC- MIPs study: Within the EPIC study, we will conduct a nested case-control study in collaboration with the US NCI to examine whether circulating levels of inflammatory markers, including acute-phase proteins, pro- and anti-inflammatory cytokines, chemokines, growth factors and angiogenesis factors are associated with prospective non-cardia GC risk. This study will contribute to an epidemiological characterization of inflammatory biomarkers involved in gastric carcinogenesis.


Selected Publications

Herrero R, Park JY, Forman D. The fight against gastric cancer – the IARC Working group report. Best Practice & Research: Clinical Gastroenterology, 28:1107-1114.

Greenberg ER and Park JY. Effectiveness of Helicobacter pylori eradication. In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 64-71.

Park JY, von Karsa L and Herrero R. Prevention and screening of gastric cancer. Clinical Endoscopy, 47:478-489.

Park JY, Greenberg ER, Parsonnet, J et al. Summary of IARC Working Group Meeting on Helicobacter pylori eradication as a strategy for preventing gastric cancer. In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 1-4.

Park JY, Forman D, Greenberg ER and Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: Are more trials needed? Current Oncology Reports, 15(6):517-525.

Scientific Societies Membership

• Associate Member of the American Association for Cancer Research
• Young Investigator Member of the European Association for Cancer Research

Prizes, Honours

• Women in Cancer Research (WICR) Scholar Award, American Association for Cancer Research, USA
• IARC Postdoctoral Fellowship (jointly supported by the EU Marie Curie Actions-People-COFUND) (Nov 2010- Nov 2012)